MYOV - MYOVANT SCIENCES ()

MYOVのニュース

   Robert W. Baird Stick to Their Buy Rating for Myovant Sciences By Investing.com  2021/03/25 14:07:52 Investing.com
Robert W. Baird Stick to Their Buy Rating for Myovant Sciences
   U.S. Uterine Fibroid Treatment Market | Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems  2021/03/23 05:59:29 OpenPR
U.S. Uterine Fibroid Treatment Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Earnings Scheduled For February 11, 2021  2021/02/11 08:51:42 Benzinga
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss at $0.55 per share on revenue of $54.86 million. • AllianceBernstein Holding (NYSE: AB ) is expected to report quarterly earnings at $0.81 per share on revenue of $805.56 million. • Applied Genetic (NASDAQ: AGTC ) is likely to report earnings for its second quarter. • Alnylam Pharmaceuticals (NASDAQ: ALNY ) is projected to report quarterly loss at $1.76 per share on revenue of $146.07 million. • Alithya Group (NASDAQ: ALYA ) is expected to report earnings for its third quarter. • AstraZeneca (NASDAQ: AZN ) is likely to report quarterly earnings at $0.68 per share on revenue of $6.97 billion. • Coca-Cola European (NYSE: CCEP ) is expected to report earnings for its fourth quarter. • Cohu (NASDAQ: COHU ) is expected to report quarterly earnings at $0.61 per share on revenue of $197.76 million. • CSP (NASDAQ: CSPI ) is estimated to report earnings for its first quarter.
   Myovant Sciences (MYOV) to Release Quarterly Earnings on Thursday  2021/02/09 08:42:41 Transcript Daily
Myovant Sciences (NYSE:MYOV) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, February 11th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link. Myovant Sciences (NYSE:MYOV) last issued its […]
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Earnings Scheduled For February 11, 2021  2021/02/11 08:51:42 Benzinga
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss at $0.55 per share on revenue of $54.86 million. • AllianceBernstein Holding (NYSE: AB ) is expected to report quarterly earnings at $0.81 per share on revenue of $805.56 million. • Applied Genetic (NASDAQ: AGTC ) is likely to report earnings for its second quarter. • Alnylam Pharmaceuticals (NASDAQ: ALNY ) is projected to report quarterly loss at $1.76 per share on revenue of $146.07 million. • Alithya Group (NASDAQ: ALYA ) is expected to report earnings for its third quarter. • AstraZeneca (NASDAQ: AZN ) is likely to report quarterly earnings at $0.68 per share on revenue of $6.97 billion. • Coca-Cola European (NYSE: CCEP ) is expected to report earnings for its fourth quarter. • Cohu (NASDAQ: COHU ) is expected to report quarterly earnings at $0.61 per share on revenue of $197.76 million. • CSP (NASDAQ: CSPI ) is estimated to report earnings for its first quarter.
   Myovant Sciences (MYOV) to Release Quarterly Earnings on Thursday  2021/02/09 08:42:41 Transcript Daily
Myovant Sciences (NYSE:MYOV) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, February 11th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link. Myovant Sciences (NYSE:MYOV) last issued its […]
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   5 Top Stock Gainers for Monday: Myovant Sciences, Yelp  2020/12/28 21:24:18 The Street
Myovant Services, Yelp, Greenpro Capital, Live Oak Acquisition and Gevo.
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   5 Top Stock Gainers for Monday: Myovant Sciences, Yelp  2020/12/28 21:24:18 The Street
Myovant Services, Yelp, Greenpro Capital, Live Oak Acquisition and Gevo.
   Why These 4 Health Care Stocks Are Moving Today  2020/12/28 19:10:48 Benzinga
Osmotica Pharmaceuticals (NASDAQ: OSMT ) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica Pharmaceuticals shares traded up 9.18% to $5.59. The stock has a 52-week high of $9.67 and a 52-week low of $2.81. Myovant Sciences (NYSE: MYOV ) shares were trading higher after the company announced a collaboration with Pfizer in which the company will … Full story available on Benzinga.com
   Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion  2020/12/28 17:01:00 MarketWatch
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for…
   Deal With Pfizer Sends Myovant Shares Higher: What Investors Need To Know  2020/12/28 10:50:00 Benzinga
Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. …

calendar